| Company/Division name | Evonik |
| Parent company | Evonik |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Offshore, work was done: | In-house |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Lafayette |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceutical drugs |
| What non-domestic negative factors made offshoring less attractive? | Green considerations |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Eco-system synergies, Government Incentives, Proximity to customers/market |
